MedPath

CURIUM US LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

6

Active:2
Completed:1

Trial Phases

2 Phases

Phase 2:1
Phase 3:4

Drug Approvals

15

FDA:15

Drug Approvals

Pulmotech MAA

Approval Date
Aug 1, 2023
FDA

Technescan HDP

Approval Date
Dec 20, 2022
FDA

Ioflupane I 123

Approval Date
Dec 16, 2022
FDA

Ultratag

Approval Date
Dec 16, 2022
FDA

Xenon, Xe-133

Approval Date
Dec 15, 2022
FDA

Technescan MAG3

Approval Date
Dec 13, 2022
FDA

Ultra-Technekow

Approval Date
Jun 9, 2022
FDA

Technetium Tc 99m Sestamibi

Approval Date
May 19, 2022
FDA

OCTREOSCAN

Approval Date
Feb 21, 2022
FDA

Detectnet

Approval Date
Dec 22, 2021
FDA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 3
4 (80.0%)
Phase 2
1 (20.0%)

Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer

Phase 3
Active, not recruiting
Conditions
Prostate Cancer
Prostate Adenocarcinoma
Biochemical Recurrence of Malignant Neoplasm of Prostate
Interventions
First Posted Date
2024-01-31
Last Posted Date
2025-06-10
Lead Sponsor
Curium US LLC
Target Recruit Count
235
Registration Number
NCT06235099
Locations
🇺🇸

Providence Medical Foundation, Fullerton, California, United States

🇺🇸

Tower Urology, Los Angeles, California, United States

🇺🇸

VA Greater Los Angeles Healthcare System, Los Angeles, California, United States

and more 28 locations

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

Phase 3
Recruiting
Conditions
Prostate Adenocarcinoma
Prostate Cancer
Interventions
First Posted Date
2024-01-31
Last Posted Date
2025-06-10
Lead Sponsor
Curium US LLC
Target Recruit Count
323
Registration Number
NCT06235151
Locations
🇺🇸

Arkansas Urology, Little Rock, Arkansas, United States

🇺🇸

Providence Medical Foundation, Fullerton, California, United States

🇺🇸

Tower Urology, Los Angeles, California, United States

and more 35 locations

Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer

Phase 2
Completed
Conditions
Metastasis From Malignant Tumor of Prostate (Disorder)
Interventions
First Posted Date
2022-12-16
Last Posted Date
2025-01-24
Lead Sponsor
Curium US LLC
Target Recruit Count
26
Registration Number
NCT05653856
Locations
🇺🇸

Yale University, New Haven, Connecticut, United States

🇺🇸

Edward Hines, Jr. VA Hospital, Hines, Illinois, United States

🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

and more 6 locations

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Phase 3
Active, not recruiting
Conditions
Metastasis From Malignant Tumor of Prostate
Interventions
First Posted Date
2022-01-24
Last Posted Date
2024-10-31
Lead Sponsor
Curium US LLC
Target Recruit Count
439
Registration Number
NCT05204927
Locations
🇺🇸

Arizona Institute of Urology, PPLC, Tucson, Arizona, United States

🇺🇸

Providence Medical Foundation, Fullerton, California, United States

🇺🇸

Long Beach Memorial Center, Long Beach, California, United States

and more 47 locations

Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)

Conditions
Neuroendocrine Tumors
First Posted Date
2020-04-06
Last Posted Date
2020-10-09
Lead Sponsor
Curium US LLC
Registration Number
NCT04334837

News

No news found
© Copyright 2025. All Rights Reserved by MedPath